Antitumor Protection by NGcGM3/VSSP Vaccine Against Transfected B16 Mouse Melanona Cells Overexpressing N-Glycolylated gangliosides
- Autores
- Segatori, Valeria Inés; Otero, Laura; Fernandez, Luis Enrique; Gomez, Daniel Eduardo; Alonso, Daniel Fernando; Gabri, Mariano Rolando
- Año de publicación
- 2012
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Background: Cancer vaccines are designed to modulate immunological responses against tumor cells through the presentation of tumor antigens. Materials and Methods: The mouse mRNA of the cytidine monophospho-N-acetylneuraminic acid hydroxylase (Cmah) gene, the enzyme that catalyzes the synthesis of N-glycolylneuraminic acid (NGc), was cloned and transfected into the B16 melanoma cell line. Transfected cells (B16-H) were characterized and used as an NGcGM3-positive primary tumor model for the evaluation of the therapeutic activity of the NGcGM3/VSSP vaccine. Results: The presence of NGcGM3 in B16-H cells promoted proliferation and adhesion in vitro, but resulted in reduced tumorigenicity in vivo. However, B16-H cells developed growing tumors in mice where NGcGM3/VSSP vaccination induced a therapeutic antitumor activity. NGcGM3/VSSP was ineffective in mice inoculated with parental B16 or B16-H cells that had lost NGcGM3 expression. Conclusion: The presence of NGcGM3 in tumor cells is critical for the antitumor activity of NGcGM3/VSSP vaccine.
Fil: Segatori, Valeria Inés. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Otero, Laura. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Fernandez, Luis Enrique. Instituto de Inmunología Molecular; Cuba
Fil: Gomez, Daniel Eduardo. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Alonso, Daniel Fernando. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Gabri, Mariano Rolando. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina - Materia
-
SIALIC ACID
N-GLYCOLYLATED GANGLIOSIDES
CYTIDINE MONOPHOSPHO-N-ACETYLNEURAMINIC HYDROXYLASE
CANCER
IMMUNOTHERAPY - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/195190
Ver los metadatos del registro completo
id |
CONICETDig_3d76eeddb7de60939a21666bdced30f7 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/195190 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Antitumor Protection by NGcGM3/VSSP Vaccine Against Transfected B16 Mouse Melanona Cells Overexpressing N-Glycolylated gangliosidesSegatori, Valeria InésOtero, LauraFernandez, Luis EnriqueGomez, Daniel EduardoAlonso, Daniel FernandoGabri, Mariano RolandoSIALIC ACIDN-GLYCOLYLATED GANGLIOSIDESCYTIDINE MONOPHOSPHO-N-ACETYLNEURAMINIC HYDROXYLASECANCERIMMUNOTHERAPYhttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Background: Cancer vaccines are designed to modulate immunological responses against tumor cells through the presentation of tumor antigens. Materials and Methods: The mouse mRNA of the cytidine monophospho-N-acetylneuraminic acid hydroxylase (Cmah) gene, the enzyme that catalyzes the synthesis of N-glycolylneuraminic acid (NGc), was cloned and transfected into the B16 melanoma cell line. Transfected cells (B16-H) were characterized and used as an NGcGM3-positive primary tumor model for the evaluation of the therapeutic activity of the NGcGM3/VSSP vaccine. Results: The presence of NGcGM3 in B16-H cells promoted proliferation and adhesion in vitro, but resulted in reduced tumorigenicity in vivo. However, B16-H cells developed growing tumors in mice where NGcGM3/VSSP vaccination induced a therapeutic antitumor activity. NGcGM3/VSSP was ineffective in mice inoculated with parental B16 or B16-H cells that had lost NGcGM3 expression. Conclusion: The presence of NGcGM3 in tumor cells is critical for the antitumor activity of NGcGM3/VSSP vaccine.Fil: Segatori, Valeria Inés. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Otero, Laura. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Fernandez, Luis Enrique. Instituto de Inmunología Molecular; CubaFil: Gomez, Daniel Eduardo. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Alonso, Daniel Fernando. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Gabri, Mariano Rolando. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaInt Inst Anticancer Research2012-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/195190Segatori, Valeria Inés; Otero, Laura; Fernandez, Luis Enrique; Gomez, Daniel Eduardo; Alonso, Daniel Fernando; et al.; Antitumor Protection by NGcGM3/VSSP Vaccine Against Transfected B16 Mouse Melanona Cells Overexpressing N-Glycolylated gangliosides; Int Inst Anticancer Research; In Vivo; 26; 4; 7-2012; 609-6170258-851X1791-7549CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://iv.iiarjournals.org/content/26/4/609/tab-figures-datainfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:53:44Zoai:ri.conicet.gov.ar:11336/195190instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:53:44.448CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Antitumor Protection by NGcGM3/VSSP Vaccine Against Transfected B16 Mouse Melanona Cells Overexpressing N-Glycolylated gangliosides |
title |
Antitumor Protection by NGcGM3/VSSP Vaccine Against Transfected B16 Mouse Melanona Cells Overexpressing N-Glycolylated gangliosides |
spellingShingle |
Antitumor Protection by NGcGM3/VSSP Vaccine Against Transfected B16 Mouse Melanona Cells Overexpressing N-Glycolylated gangliosides Segatori, Valeria Inés SIALIC ACID N-GLYCOLYLATED GANGLIOSIDES CYTIDINE MONOPHOSPHO-N-ACETYLNEURAMINIC HYDROXYLASE CANCER IMMUNOTHERAPY |
title_short |
Antitumor Protection by NGcGM3/VSSP Vaccine Against Transfected B16 Mouse Melanona Cells Overexpressing N-Glycolylated gangliosides |
title_full |
Antitumor Protection by NGcGM3/VSSP Vaccine Against Transfected B16 Mouse Melanona Cells Overexpressing N-Glycolylated gangliosides |
title_fullStr |
Antitumor Protection by NGcGM3/VSSP Vaccine Against Transfected B16 Mouse Melanona Cells Overexpressing N-Glycolylated gangliosides |
title_full_unstemmed |
Antitumor Protection by NGcGM3/VSSP Vaccine Against Transfected B16 Mouse Melanona Cells Overexpressing N-Glycolylated gangliosides |
title_sort |
Antitumor Protection by NGcGM3/VSSP Vaccine Against Transfected B16 Mouse Melanona Cells Overexpressing N-Glycolylated gangliosides |
dc.creator.none.fl_str_mv |
Segatori, Valeria Inés Otero, Laura Fernandez, Luis Enrique Gomez, Daniel Eduardo Alonso, Daniel Fernando Gabri, Mariano Rolando |
author |
Segatori, Valeria Inés |
author_facet |
Segatori, Valeria Inés Otero, Laura Fernandez, Luis Enrique Gomez, Daniel Eduardo Alonso, Daniel Fernando Gabri, Mariano Rolando |
author_role |
author |
author2 |
Otero, Laura Fernandez, Luis Enrique Gomez, Daniel Eduardo Alonso, Daniel Fernando Gabri, Mariano Rolando |
author2_role |
author author author author author |
dc.subject.none.fl_str_mv |
SIALIC ACID N-GLYCOLYLATED GANGLIOSIDES CYTIDINE MONOPHOSPHO-N-ACETYLNEURAMINIC HYDROXYLASE CANCER IMMUNOTHERAPY |
topic |
SIALIC ACID N-GLYCOLYLATED GANGLIOSIDES CYTIDINE MONOPHOSPHO-N-ACETYLNEURAMINIC HYDROXYLASE CANCER IMMUNOTHERAPY |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/1.6 https://purl.org/becyt/ford/1 |
dc.description.none.fl_txt_mv |
Background: Cancer vaccines are designed to modulate immunological responses against tumor cells through the presentation of tumor antigens. Materials and Methods: The mouse mRNA of the cytidine monophospho-N-acetylneuraminic acid hydroxylase (Cmah) gene, the enzyme that catalyzes the synthesis of N-glycolylneuraminic acid (NGc), was cloned and transfected into the B16 melanoma cell line. Transfected cells (B16-H) were characterized and used as an NGcGM3-positive primary tumor model for the evaluation of the therapeutic activity of the NGcGM3/VSSP vaccine. Results: The presence of NGcGM3 in B16-H cells promoted proliferation and adhesion in vitro, but resulted in reduced tumorigenicity in vivo. However, B16-H cells developed growing tumors in mice where NGcGM3/VSSP vaccination induced a therapeutic antitumor activity. NGcGM3/VSSP was ineffective in mice inoculated with parental B16 or B16-H cells that had lost NGcGM3 expression. Conclusion: The presence of NGcGM3 in tumor cells is critical for the antitumor activity of NGcGM3/VSSP vaccine. Fil: Segatori, Valeria Inés. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Otero, Laura. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Fernandez, Luis Enrique. Instituto de Inmunología Molecular; Cuba Fil: Gomez, Daniel Eduardo. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Alonso, Daniel Fernando. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Gabri, Mariano Rolando. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina |
description |
Background: Cancer vaccines are designed to modulate immunological responses against tumor cells through the presentation of tumor antigens. Materials and Methods: The mouse mRNA of the cytidine monophospho-N-acetylneuraminic acid hydroxylase (Cmah) gene, the enzyme that catalyzes the synthesis of N-glycolylneuraminic acid (NGc), was cloned and transfected into the B16 melanoma cell line. Transfected cells (B16-H) were characterized and used as an NGcGM3-positive primary tumor model for the evaluation of the therapeutic activity of the NGcGM3/VSSP vaccine. Results: The presence of NGcGM3 in B16-H cells promoted proliferation and adhesion in vitro, but resulted in reduced tumorigenicity in vivo. However, B16-H cells developed growing tumors in mice where NGcGM3/VSSP vaccination induced a therapeutic antitumor activity. NGcGM3/VSSP was ineffective in mice inoculated with parental B16 or B16-H cells that had lost NGcGM3 expression. Conclusion: The presence of NGcGM3 in tumor cells is critical for the antitumor activity of NGcGM3/VSSP vaccine. |
publishDate |
2012 |
dc.date.none.fl_str_mv |
2012-07 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/195190 Segatori, Valeria Inés; Otero, Laura; Fernandez, Luis Enrique; Gomez, Daniel Eduardo; Alonso, Daniel Fernando; et al.; Antitumor Protection by NGcGM3/VSSP Vaccine Against Transfected B16 Mouse Melanona Cells Overexpressing N-Glycolylated gangliosides; Int Inst Anticancer Research; In Vivo; 26; 4; 7-2012; 609-617 0258-851X 1791-7549 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/195190 |
identifier_str_mv |
Segatori, Valeria Inés; Otero, Laura; Fernandez, Luis Enrique; Gomez, Daniel Eduardo; Alonso, Daniel Fernando; et al.; Antitumor Protection by NGcGM3/VSSP Vaccine Against Transfected B16 Mouse Melanona Cells Overexpressing N-Glycolylated gangliosides; Int Inst Anticancer Research; In Vivo; 26; 4; 7-2012; 609-617 0258-851X 1791-7549 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://iv.iiarjournals.org/content/26/4/609/tab-figures-data |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Int Inst Anticancer Research |
publisher.none.fl_str_mv |
Int Inst Anticancer Research |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842269244182495232 |
score |
13.13397 |